Diagnostic performance of (68)Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study.
Diagnostic performance of (68)Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study.
复制标题
DOI：
10.1007/s00259-021-05261-y
复制
发表时间：
2021-09
影响因子：
9.1
通讯作者：
Burger IA
中科院分区：
文献类型：
--
作者：
Ferraro DA;Becker AS;Kranzbühler B;Mebert I;Baltensperger A;Zeimpekis KG;Grünig H;Messerli M;Rupp NJ;Rueschoff JH;Mortezavi A;Donati OF;Sapienza MT;Eberli D;Burger IA
超声引导活检(US活检)10-12个核心对于临床上有意义的前列腺癌(SigPCa)的敏感度低于最佳。如果US活检是阴性的，建议使用磁共振成像(MRI)引导的活检，尽管对于前列腺成像报告和数据系统(PIRADS)评分为3-5的病变的特异性较低。使用高精度的成像方式进行筛查和活检指导可以减少不必要的活检次数，减少副作用。本研究的目的是评价68Ga标记的前列腺特异性膜抗原正电子发射断层扫描/磁共振成像在检测和定位原发性前列腺癌(ISUP分级为3级和/或癌核长度 ≥ 为6 mm)和引导活检方面的作用。前瞻性、开放标记、单中心、非随机诊断准确性研究，包括前列腺特异性抗原(PSA)水平升高和多参数磁共振成像(≥)上可疑病变(PIRADS MpMRI 3)疑似前列腺癌的患者。2017年5月至2019年2月，42名患者接受了PSMA-PET/MRI检查，随后在PSMA-PET/MRI引导下和基于切片的饱和模板活检。主要结果是以切片饱和模板活检为参考标准，PSMA-PET/MRI对活检指导的准确性。62%的患者存在SigPCA。以患者为基础的SigPCA的灵敏度、特异度、阴性预测值、阳性预测值和准确度分别为96%、81%、93%、89%和90%。1例为PSMA阴性的SigPCA。9个假阳性病变中有8个对应于前列腺癌，6个假阴性病变中有1个在前列腺切除术中为阴性。PSMA-PET/MRI对SigPCA的检测具有较高的准确性，是筛选疑似PCa患者进行活检的一种有前景的工具。该试验于2017年6月15日在(https://clinicaltrials.gov/ct2/show/NCT03187990).上以“正电子发射断层扫描/磁共振成像引导下的前列腺特异性抗原升高男性患者的活检”(NCT03187990)的名称进行了回顾登记网上版载有补充材料，可在10.1007/s00259-021-05261-y查阅。
Ultrasound-guided biopsy (US biopsy) with 10–12 cores has a suboptimal sensitivity for clinically significant prostate cancer (sigPCa). If US biopsy is negative, magnetic resonance imaging (MRI)–guided biopsy is recommended, despite a low specificity for lesions with score 3–5 on Prostate Imaging Reporting and Data System (PIRADS). Screening and biopsy guidance using an imaging modality with high accuracy could reduce the number of unnecessary biopsies, reducing side effects. The aim of this study was to assess the performance of positron emission tomography/MRI with 68Ga-labeled prostate-specific membrane antigen (PSMA-PET/MRI) to detect and localize primary sigPCa (ISUP grade group 3 and/or cancer core length ≥ 6 mm) and guide biopsy. Prospective, open-label, single-center, non-randomized, diagnostic accuracy study including patients with suspected PCa by elevation of prostate-specific antigen (PSA) level and a suspicious lesion (PIRADS ≥3) on multiparametric MRI (mpMRI). Forty-two patients underwent PSMA-PET/MRI followed by both PSMA-PET/MRI-guided and section-based saturation template biopsy between May 2017 and February 2019. Primary outcome was the accuracy of PSMA-PET/MRI for biopsy guidance using section-based saturation template biopsy as the reference standard. SigPCa was found in 62% of the patients. Patient-based sensitivity, specificity, negative and positive predictive value, and accuracy for sigPCa were 96%, 81%, 93%, 89%, and 90%, respectively. One patient had PSMA-negative sigPCa. Eight of nine false-positive lesions corresponded to cancer on prostatectomy and one in six false-negative lesions was negative on prostatectomy. PSMA-PET/MRI has a high accuracy for detecting sigPCa and is a promising tool to select patients with suspicion of PCa for biopsy. This trial was retrospectively registered under the name “Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men with Elevated PSA” (NCT03187990) on 06/15/2017 (https://clinicaltrials.gov/ct2/show/NCT03187990). The online version contains supplementary material available at 10.1007/s00259-021-05261-y.
登录
查看更多内容
影响因子：
51.1
作者：
Rouviere, Olivier;Puech, Philippe;Grenier, Nicolas
通讯作者：
Grenier, Nicolas
DOI：
10.1007/s00259-019-04620-0
发表时间：
2020-07-01
影响因子：
9.1
作者：
Donato, Peter;Morton, Andrew;Roberts, Matthew J.
通讯作者：
Roberts, Matthew J.
影响因子：
4.6
作者：
Bravaccini S;Puccetti M;Bocchini M;Ravaioli S;Celli M;Scarpi E;De Giorgi U;Tumedei MM;Raulli G;Cardinale L;Paganelli G
通讯作者：
Paganelli G
DOI：
10.1056/nejmoa1801993
发表时间：
2018-05-10
期刊：
The New England journal of medicine
影响因子：
--
作者：
通讯作者：
--
影响因子：
4.7
作者：
Hupe, Marie Christine;Philippi, Christian;Offermann, Anne
通讯作者：
Offermann, Anne